Danaher Life Sciences and WuXi Biologics Jointly Launch Industry Initiative and Unveil Integrated Biotherapeutics Solutions

Recently, under the guidance of the China Biochemical Pharmaceutical Industry Association, the Biologics Ecosystem Innovation and Cooperation Summit, co-hosted by Danaher Life Sciences and WuXi Biologics, was successfully held at the Jumeirah Himalayas Hotel in Shanghai.

A Gathering of Industry Luminaries, A Constellation of Distinguished Experts

On the afternoon of the first day, the Danaher Life Sciences New Product Launch and the WuXi Biologics Integrated Technology Empowerment Platform Promotional Conference officially kicked off the proceedings. Mr. Li Bing, President of Danaher Life Sciences China, and Dr. Zhou Weichang, Executive Vice President and Chief Technology Officer of WuXi Biologics, delivered joint opening remarks. They extended a warm welcome to all attending media representatives and reviewed the original vision behind hosting this summit. The arduous battle against the COVID-19 pandemic has made every biopharmaceutical professional more acutely aware of the historical mission they bear. The rapid research, development, and production of COVID-19 vaccines and therapeutics would not have been possible without close collaboration and relentless innovation across all sectors of the biologics industry. Looking ahead, the continuous advancement and upgrading of biologics will require even deeper collaboration and extensive coordination among all industry stakeholders.

Danaher Life Sciences and WuXi Biologics jointly recognize that to cultivate an ecosystem conducive to the sustainable and healthy development of the biopharmaceutical industry, it is essential to build a broad industry consensus. This consensus must foster a collaborative landscape where basic scientific research, product development, commercial manufacturing, and relevant government regulatory frameworks are mutually aligned, jointly driving progress and ensuring sound growth. As leading enablers in the global pharmaceutical industry, Danaher Life Sciences and WuXi Biologics jointly issue this initiative and call upon all stakeholders across the biologics sector to reach a broad consensus, strengthen cooperation, and advance in synergy. We are committed to making unremitting efforts to establish an ecosystem that supports the healthy and sustainable development of the biopharmaceutical industry.

Mr. Li Bing, President of Danaher Life Sciences, Greater China, and Dr. Zhou Weichang, Executive Vice President and Chief Technology Officer of WuXi Biologics, jointly delivered remarks.

During the media Q&A session, President Li Bing provided in-depth responses regarding Danaher Life Sciences' localization strategy and its role within the ecosystem. In terms of localization, the Danaher Life Sciences platform has established an Application R&D Center and a Bioprocessing Development Center in Shanghai Hongqiao and Zhangjiang, Pudong, showcasing equipment and methodologies in a workflow format within the laboratory to provide users with an immersive experience of real-world application scenarios; this year, Pall Group completed the acquisition of the Pall-Ostar joint venture; and localized R&D has also been conducted for Beckman's flow cytometry cell sorter.

Within the ecosystem, Danaher Life Sciences provides a comprehensive portfolio of products for biologics R&D, spanning from target discovery and antigen preparation to antibody generation. For manufacturing, it delivers process solutions covering upstream and downstream processing through to formulation and filling. In quality control to ensure drug safety and efficacy, it offers a complete suite of analytical testing solutions, ranging from morphology, structure, and function to residual impurities. By leveraging its proprietary products and solutions, Danaher Life Sciences empowers more biopharmaceutical partners, facilitating the integration and streamlined operation of biologics workflows, thereby driving the stable and healthy development of the ecosystem.

Media Interview with Mr. Li Bing, President of Danaher Life Sciences China

Dr. Zhou Weichang then shared WuXi Biologics’ contributions to empowering its partners in the fight against the COVID-19 pandemic. To date, the company has mobilized over 3,000 scientists dedicated to the research, development, and manufacturing of COVID-19 therapeutics, supporting more than 12 anti-COVID-19 neutralizing antibodies in submitting 20 Investigational New Drug (IND) applications globally. The COVID-19 vaccines and neutralizing antibodies produced by WuXi Biologics have benefited over 1 million COVID-19 patients and 200 million people worldwide. This achievement is underpinned by the integrated biopharmaceutical capabilities and technology platforms meticulously honed over a decade. Leveraging these strengths, WuXi Biologics empowered Vir Biotechnology to accelerate the development of its anti-COVID-19 neutralizing antibody from DNA to Emergency Use Authorization (EUA), setting an industry record. Driven by a relentless dedication to excellence, unwavering execution to deliver on critical missions, and unprecedented speed, WuXi Biologics has earned the complete trust of its partners, injecting powerful momentum into the global campaign to swiftly overcome the pandemic.

Dr. Zhou Weichang, Executive Vice President and Chief Technology Officer of WuXi Biologics, Gives a Media Interview

Following the press conference, Danaher Life Sciences unveiled its biopharmaceutical solutions. Dr. Wang Jun, Chief Scientist at Pall China; Li Weijing, Market Development Manager at Leica; Xu Mengjie, Applications Manager at Molecular Devices; Zhang Yinsheng, Product Manager at Beckman Coulter; and Tang Kai, Market Development Manager at Cytiva, provided a comprehensive overview of Danaher Life Sciences' biopharmaceutical solutions from four key perspectives: target discovery, cell line development, manufacturing processes, and quality analysis. Danaher Life Sciences' biopharmaceutical solutions offer an end-to-end workflow and product portfolio spanning R&D, process development, clinical trials, and commercial manufacturing, helping customers accelerate the commercialization of antibodies, novel vaccines, and cell and gene therapies.

Featuring a curated selection of premium products and a steady stream of innovations, Danaher Life Sciences is proudly launching four major high-tech new products and one integrated solution for its 2021 biopharmaceutical portfolio. These include: the CytoFLEX SRT benchtop sorting flow cytometer from Beckman Coulter, which delivers exceptional performance in a compact footprint; the ImageXpress Confocal HT from Molecular Devices, an all-in-one intelligent confocal high-content system for high-speed imaging and analysis; the ZenoTOF 7600 from SCIEX, an innovative high-resolution time-of-flight mass spectrometry system featuring multiple energy-tunable ion fragmentation modes; the BMS online management system from Pall Corporation, capable of continuous buffer production; and the Leica Cell Dive highly multiplexed tissue imaging and analysis solution, which enables imaging and analysis of over 60 proteins on a single tissue section. Together, these new products and solutions will deliver a transformative user experience in tissue protein target discovery, monoclonal cell sorting, biopharmaceutical characterization, and manufacturing process buffer management.

The highlight of the evening unfolded at the VIP dinner, where President Li Bing and Dr. Zhou Weichang took the stage alongside Academician Zhao Guoping of the Shanghai Institute for Nutrition and Health, Chinese Academy of Sciences; Mr. Hu Wenyan, Executive Vice President and Secretary-General of the China Biochemical Pharmaceutical Industry Association; Ms. Wei Chunyan, Vice President of Government Affairs for China at Danaher; Mr. Li Zhenfu, Founder of TopFund Capital; Dr. Tang Jun of the Shanghai Biomedical Science and Technology Industry Promotion Center; Mr. Li Hangwen, CEO of SWMune Bio; and Dr. Hei Yongjiang, CEO of Yuheng Pharmaceutical. Together, they launched a biopharmaceutical industry initiative encapsulated by the slogan: “Quality as the foundation, innovation as the driver, technology as the enabler, and collaboration for win-win success.” Each character of this sixteen-character pledge resonated with strength and conviction, striking a deep chord with over 150 biopharmaceutical industry leaders in attendance.

Launch Ceremony of the Biopharmaceutical Industry Initiative Declaration

An initiative is not merely a slogan, but an attitude that calls for concrete action. Let us unite in building our shared vision, harness the prevailing momentum, and together look forward to an even more remarkable journey of implementation ahead!

The publication of the Industry Initiative Declaration has garnered widespread endorsement from professionals in the biologics sector. The following day, the 2021 Biologics Ecosystem Innovation and Cooperation Summit opened in Zhangjiang, Pudong. Over 30 distinguished representatives from academia, corporate leadership, industry associations, regulatory authorities, and investment institutions, alongside more than 400 biologics practitioners from across China, engaged in rigorous and professional discussions on numerous current industry hot topics, including recent advances in biologics R&D and the opportunities and challenges associated with biologics industrialization. Several discussions drew particular attention and widespread interest, including retrospectives and insights on therapeutic live biotherapeutics, development trends and clinical differentiation strategies for bispecific antibodies, leveraging innovation to ensure competitiveness in a crowded biologics landscape, opportunities and challenges in novel vaccine development, and the formulation of optimal commercialization strategies.

About Danaher Life Sciences

Danaher is a global innovator in the life sciences services sector. Committed to delivering high-quality products and services, Danaher helps customers accelerate life sciences research, address challenges in the analytical field, advance medical diagnostics, and enhance laboratory productivity. Danaher’s corporate mission is to realize the limitless potential of life. The company’s products are designed to help people worldwide live healthier, safer, and more comfortable lives.

Danaher Life Sciences China was established on June 1, 2019, with the aim of taking root in the Chinese market to deliver superior products and services to local customers. Guided by the vision of "Focus on Life, Collaborate for Shared Success" and the mission to "Share Global Science, Advance Health for All," the region is dedicated to developing comprehensive, integrated solutions for precision medicine and biopharmaceuticals.

Currently, the platform enterprises include Integrated DNA Technologies, Inc., Beckman Coulter Commercial Enterprise (China) Co., Ltd., Molecular Devices (Shanghai) Co., Ltd., SCIEX (Shanghai) Analytical Instrument Trading Co., Ltd., Tianjin Bonna-Agela Technologies Co., Ltd., Leica Microsystems (Shanghai) Trading Co., Ltd., and Pall (China) Co., Ltd.

About WuXi Biologics

WuXi Biologics (Stock Code: 2269.HK), as a Hong Kong-listed company, is a globally leading open, integrated biologics capability and technology empowerment platform. The company provides comprehensive end-to-end research and development services to global biopharmaceutical and biotechnology companies, helping anyone and any company discover, develop, and manufacture biologics. It enables the entire process from concept to commercial manufacturing, accelerating the global biologics R&D process, reducing R&D costs, and benefiting patients.

As of March 22, 2021, the total number of projects under development on the WuXi Biologics platform reached 361, including 190 in the preclinical stage, 137 in the early clinical stage (Phase I and Phase II), 32 in the late-stage clinical stage (Phase III), and 2 in commercial manufacturing. It is expected that after 2024, the combined capacity of the biopharmaceutical manufacturing facilities planned by the company in China, Ireland, the United States, Germany, and Singapore will reach 430,000 liters, which will strongly ensure the company's ability to deliver biologics meeting global quality standards to customers through a robust and comprehensive global supply chain network.

WuXi Biologics regards Environmental, Social, and Governance (ESG) as an integral component of its business development and corporate values, and has established an ESG committee led by the Chief Executive Officer to fulfill its commitment to sustainable development while enhancing operational efficiency.